KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Twist Bioscience (TWST) Research & Development (2018 - 2025)

Historic Research & Development for Twist Bioscience (TWST) over the last 8 years, with Q4 2025 value amounting to $17.1 million.

  • Twist Bioscience's Research & Development fell 1960.39% to $17.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $76.1 million, marking a year-over-year decrease of 1454.2%. This contributed to the annual value of $80.3 million for FY2025, which is 1163.1% down from last year.
  • Latest data reveals that Twist Bioscience reported Research & Development of $17.1 million as of Q4 2025, which was down 1960.39% from $17.0 million recorded in Q3 2025.
  • Over the past 5 years, Twist Bioscience's Research & Development peaked at $36.8 million during Q2 2022, and registered a low of $15.8 million during Q1 2021.
  • Its 5-year average for Research & Development is $23.5 million, with a median of $22.9 million in 2021.
  • Its Research & Development has fluctuated over the past 5 years, first skyrocketed by 9777.72% in 2022, then tumbled by 3342.02% in 2023.
  • Twist Bioscience's Research & Development (Quarter) stood at $22.6 million in 2021, then skyrocketed by 38.06% to $31.2 million in 2022, then dropped by 26.06% to $23.1 million in 2023, then fell by 7.76% to $21.3 million in 2024, then dropped by 19.6% to $17.1 million in 2025.
  • Its last three reported values are $17.1 million in Q4 2025, $17.0 million for Q3 2025, and $18.0 million during Q2 2025.